All News

EULAR,Podcast,2021

EULAR 2021 - Day 1 Podcasts

d Jack Cush, MD

Check out this compilation of our EULAR 2021 Day 1 broadcasts below.



You can follow the EULAR 2021 RheumNow podcasts on iTunes and Soundclound.com



Listen by Clicking below:



Day 1a

Read Article
Q-DAPSA (DAPSA + CRP), validated as a clinical measure of PsA disease activity in both practice & research from 5 centers in Berlin, 104 PsA pts. Let's get more studies to better understand the power of this measure. Poster #POS1069 #EULAR2021 @RheumNow https://t.co/X4UWGwH5i5 https://t.co/J7EpOjTjhe

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
Dr Lukas presents data showing possibility of tapering a range of TNF in AxSpA patients in remission 162/184 (88.0%) LDA in progressive spacing group vs 173/189 (91.5%) in continued at 1 year.@RheumNow #EULAR2021 Abstr#0138

Richard Conway RichardPAConway ( View Tweet)

Honoured to be part of the irAE session at #EULAR2021, with some great talks (and then also mine), including: - Anne Bass @lovetolearn27 @HSpecialSurgery on irAE mechanisms - Maria Suarez-Almazor @MDAndersonNews on irAEs in the clinic Well worth tuning into! @RheumNow https://t.co/MN1IcLKv6u
David Liew drdavidliew ( View Tweet)
Abst#OP0137 at #EULAR2021: ➡️TNFi use for at least 1 year decreased radiographic sacroiliitis progression in early AxSpA in this ten year multicenter study of the German Spondyloarthritis Inception cohort (GESPIC) . ➡️This effect becomes evident 2-4 years after tx. @RheumNow https://t.co/GNnYqYmxhl
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
SPACING trial: possible to taper TNFi in AxSpA pts in LDA ⭐️Tapering of TNFi in axSpA resulted in 88% BASDAI<4 compared to 91.5% in unchanged group ⭐️adalimumab spaced out to q35 days Abs#OP0138 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

PROs in Spa and PSA: Dr. Rachel Tate ( @uptoTate) https://t.co/sUXTXDXrFh

Links:

Dr. John Cush RheumNow ( View Tweet)

Based on the data, what would you do in a new SLE patient w/LN class IV who is already on a background of GC's+HCQ? @rheumnow @kidneydoc101 @Lupusreference

k dao KDAO2011 ( View Tweet)

The case for starting combo Rx for LN (rather than sequential Rx): 👉Aurora trial: voclosporin + MMF (vs. MMF only) prompt efficacy on proteinuria across all ethnic subgroups, twice more complete renal response , no major safety signals. slide 1/ #EULAR2021 @rheumnow https://t.co/TA5i9ITuL7
k dao KDAO2011 ( View Tweet)
#Digital #rheumatology in the era of #COVID-19: evidently increasing inclination of patients and physicians to use digital health apps for recording data- as informed by a national survey by @JK77775 and colleagues #EULAR2021 @ARD_BMJ https://t.co/Uo60qZurhG
Latika LatikaGupta_ ( View Tweet)
So it comes down to the grand question: how on earth do we actually monitor disease activity?? "We still don't have a failsafe algorithm... relapse is both underdiagnosed & overdiagnosed" - @Sarah_L_Mackie The challenge lots of good people are working on! #EULAR2021 @RheumNow https://t.co/PUa6Ly1DQw
David Liew drdavidliew ( View Tweet)
OP0131: Pooled data from TULIP-1 and TULIP-2 show anifrolumab (anti-IFN receptor Ab) show improvement of rash and arthritis. Shows promise for drug, particularly in subset of pts with high IFN activity #EULAR2021 @RheumNow https://t.co/sddF2NRlEg
Eric Dein ejdein1 ( View Tweet)
MUC5B promoter variant is associated with interstitial lung disease. Interactions with: 👉rheumatoid arthritis 👉 age 👉 sex Check this Finnish biobank study of 250,000 individuals presented by Antti Palömaki at the Plenary Abstracts Session Wed 02/06 16:15 >LC

ARD & RMD Open ARD_BMJ ( View Tweet)

Patients selected to maximise response & minimise adverse events in RA & PsA trials. What implications does this have when we interpret the data & try to apply in clinic? #EULAR2021 https://t.co/CocKlvjme4
Dr Irwin Lim _connectedcare ( View Tweet)
Placebo response in PsA trials have more than doubled in last decade. Due to patient characteristics, patient expectations? Makes it very difficult to compare between trials #EULAR2021 https://t.co/XQk4hqrYN8
Dr Irwin Lim _connectedcare ( View Tweet)
Drug-induced ANCA-associated vasculitis: here are the ones to look for👇 - hydralazine - PTU - penicillamine - thiamazole - sofosbuvir - minocycline - carbimazole (but then a few others floating about!) VigiBase data POS0118 #EULAR2021 @RheumNow https://t.co/ujgJAJQeKY
David Liew drdavidliew ( View Tweet)
Worse dentition is associated with worse RA disease activity. And that's the tooth!🙄 from two big German cohorts @CallhoffJ POS0026 #EULAR2021 @RheumNow https://t.co/rjCQ6AtQzq
David Liew drdavidliew ( View Tweet)

COAST-V: IXE ⬇️SP-N & spinal pain in r-axSpA pts w/ or w/o ⬆️ CRP or morning stiffness. Pts treated w/ ADA re-randomized to IXE showed further⬇️in SP-N & spinal pain. Poster #POS0901 #EULAR2021 @RheumNow https://t.co/46qiqrohbX https://t.co/uB15oTwztV

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
"But, effectively communicating overdiagnosis is a challenge in light of entrenched beliefs about the benefits of testing and the culture of current journalism practices." @raymoynihan et al in @BMJ_Open. https://t.co/1DW5OIMh6R

Links:

Ivan Oransky ivanoransky ( View Tweet)

ERA & JPsA children & adolescents tx'ed w/ SEC, JUNIPERA 104wk data: longer time to flare vs PBO. NRI analysis: 87.2%, 83.7%, 67.4%, 38.4% and 24.4% achieved JIA ACR 30/50/70/90/100, respectively. No new safety signals. #EULAR2021 @RheumNow Abstract #LB004 https://t.co/reWawBWfqh https://t.co/9gzKKU1xrm

Links:

Dr. Rachel Tate uptoTate ( View Tweet)
×